ClinicalTrials.gg
RecruitingNCT05244551Updated Aug 12, 2024

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ABSK061 in Solid Tumor, sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

Read the detailed description

Escalation Part:

Dose escalation of oral ABSK061 will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. During the dose escalation part of the study, patients will receive a single dose of ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in the subsequent cycles. If the actual elimination half-life of ABSK061 is greatly exceeding that predicted, a run-in period with a single-dose and a longer drug-free observation period could be performed in subsequent patients after the Investigator and Sponsor have discussed and agreed.

Expansion Part:

When health authorities outside US require safety data in local population be provided prior to expansion part, a minimum of 3 local subjects will be enrolled and treated at the selected RDE dose level first in that country/region to evaluate the tolerability of ABSK061. The inclusion and exclusion criteria for escalation part will apply for these subjects. After similar safety and tolerability of ABSK061 in patients in the relevant locality have been confirmed by local Investigators and the Sponsor, additional patients will be allowed to enroll in the expansion part.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient should understand, sign, and date the written form prior to screening.
  2. Male or female age 18 years or older.
  3. For escalation part: patients with confirmed solid tumors who have progressed on or are intolerant of standard therapy or for whom no standard therapy exists.

For expansion Part:

  1. Patients with histologically confirmed urothelial carcinoma or cholangiocarcinoma who have progressed on or are intolerant of standard therapy or for whom no standard therapy exists.
  2. Patients must have tumors with following FGFR2/3 genetic alterations based on central laboratory test or existing test reports: Urothelial carcinoma: FGFR2/3 fusions and FGFR3 activating mutations Cholangiocarcinoma: FGFR2 fusions and/or arrangements
  3. Patients must have at least one measurable target lesion according to 1.1.
  4. Patients are willing to undergo if archival tumor tissue is not available or the archival specimen deemed inadequate or confirmed FGFR2/3 alterations from existing reports is not available.
  1. performance status 0 or 1 5. ≥3 months 6. Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study drug:
  1. (ANC) ≥1.5×109/L
  2. count (PLT) ≥ 100×109/L without transfusion requirement within 14 days before 1st dose
  3. (Hb)≥90 g/L
  4. Total (TBIL) ≤1×
  5. (AST) and alanine transaminase (ALT) ≤2.5×ULN.
  6. Serum creatinine (Cr) of ≤1.5×ULN for the reference laboratory or (Crcl) ≥ 50 mL/min based on Cockcroft-Gault formula

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to any component of the product
  2. For expansion part only: Previous treatment with FGFR pathway inhibitors or multi-kinase inhibitors which target FGFR inhibition (recommend to consult with sponsor)
  3. Has a known additional that is progressing or has required active treatment.
  4. Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication
  5. Previous anti-cancer therapy, including chemotherapy (chemotherapy with nitrosourea or mitomycin should be at least 6 weeks prior to initiation of study treatment), radiotherapy, molecular targeted therapy or other investigational drugs received ≤4 weeks; endocrine therapy ≤2 weeks or ≤5-half life (whichever is shorter) prior to initiation of study treatment.
  6. Major surgery within 4 weeks of the first dose of study drug. Note that all surgical wounds must be healed and free of infection or dehiscence.
  7. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade ≤1 severity ( V5.0) with the exception of alopecia and vitiligo.
  8. Concomitant use of the drugs/remedies that may cause pharmacokinetic drug-drug interactions; consumption of grapefruit juice, grapefruit hybrids, pomegranates, starfruit, pomelos, Seville oranges or juice products within 7 days prior to the first dose of study medication.
  9. Active central nervous system (CNS) including presence of cerebral edema, requirement for systemic treatment, disease progression due to intracranial lesions, , and other clinical symptoms related to .
  10. Impaired cardiac function or cardiac disease, including any one of the following:

    • class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure
    • Baseline prolongation of the rate- interval based on repeated demonstration of QTcF >470 ms or history of long QT interval corrected (QTc) syndrome (Note: QTc interval corrected by Fridericia's formula).
    • (LVEF) \<50% or below the institutional lower limit of normal (whichever is higher)
  11. Known (HIV) or active , or active infection; positive tests for hepatitis B virus surface antigen (HBsAg), or antibody to hepatitis B core Ag (HBcAb), or hepatitis C RNA in serum (subjects with history of hepatitis C infection but negative hepatitis C virus polymerase chain reaction (PCR) test are allowed; positive tests for HBV HBsAg or HBcAb with HBV-DNA measurements lower than 1000IU/ml can be included)
  12. Any of the following ophthalmological criteria:

    • Current evidence or previous history of retinal pigmented epithelial detachment (RPED)
    • Previous laser treatment or intra-ocular injection for treatment of macular degeneration
    • Current evidence or previous history of dry or wet age-related macular degeneration
    • Current evidence or previous history of retinal vein occlusion (RVO)
    • Current evidence or previous history of retinal degenerative diseases (eg, hereditary)
    • Current evidence or previous history of any other clinically relevant chorioretinal defect
    • Current evidence or previous history of corneal pathology such as conjunctivitis, keratopathy, corneal abrasion or ulceration
  13. Patients with /uncontrolled ascites or pleural effusion.
  14. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test within 7 days prior to the start of study drug.
  15. Non-surgically sterilized male or female patients of must agree to use highly effective methods of during the study and for up to 6 months after the last dose of study drug.
  16. Sexually active males, unless they use a condom during intercourse while taking drug and for 5 consecutive compound half-lives plus 60 days after stopping study drug, should not father a child. A condom is required to be used also by vasectomized men to prevent delivery of the drug via seminal fluid.
  17. Vaccination with a live, attenuated vaccine within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivate vaccines (e.g., COVID-19 vaccines, inactivated influenza vaccines).
  18. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    ABSK061

    Dose escalation of oral ABSK061 will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. During the dose escalation part of the study, patients will receive a single dose of ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in the subsequent cycles. If the actual elimination half-life of ABSK061 is greatly exceeding that predicted, a run-in period with a single-dose and a longer drug-free observation period could be performed in subsequent patients after the Investigator and Sponsor have discussed and agreed.

    Drug: ABSK061

Interventions

  • In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.

06

What researchers measure

Primary outcomes

  1. Incidence of DLT

    dose-limiting toxicities (DLTs)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Incidence and severity of adverse events (AEs)

    adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)

    Time frame: Through study completion, an average of half year

Secondary outcomes

  1. Cmax

    maximum observed concentration

    Time frame: Through the study completion, an average of half year

  2. Tmax

    time to maximum observed concentration

    Time frame: Through the study completion, an average of half year

  3. AUC

    area under the concentration-time curve

    Time frame: Through the study completion, an average of half year

  4. t1/2

    half-life

    Time frame: Through the study completion, an average of half year

  5. Vz/F

    apparent volume of distribution

    Time frame: Through the study completion, an average of half year

  6. CL/F

    apparent oral clearance

    Time frame: Through the study completion, an average of half year

  7. Css_max

    maximum observed concentration of steady-state

    Time frame: Through the study completion, an average of half year

  8. Css_min

    minimum observed concentration of steady/state

    Time frame: Through the study completion, an average of half year

  9. AUCss

    area under the concentration-time curve of steady/state

    Time frame: Through the study completion, an average of half year

  10. Rac

    accumulation rate

    Time frame: Through the study completion, an average of half year

  11. ORR

    Overall response rate

    Time frame: Through the study completion, an average of half year

  12. DoR

    Duration of response

    Time frame: Through the study completion, an average of half year

  13. DCR

    Disease control rate

    Time frame: from onset of PR or CR to disease progression (up to 100 months)

  14. DoR

    Duration of response

    Time frame: at 24 weeks

  15. PFS

    Progression-free survival

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

12 of 22 sites recruiting
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
    Recruiting
  • Yuan LU
    Shanghai, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515 201203, China
    Recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
    Recruiting
    • Hongtao Li, MD · Contact
    • Hongtao Li, MD · Principal investigator
    • Huan Zhou, MD · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing, China
    Not yet recruiting
    • Ning Li, MD · Contact
    • Ning Li, MD · Principal investigator
  • Chongqing Daping Hospital
    Chongqing, Chongqing, China
    Not yet recruiting
    • Mengxia Li, MD · Contact
    • Mengxia Li, MD · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Not yet recruiting
    • Zhiyong He, MD · Contact
    • Zhiyong He, MD · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Gongshu District, China
    Recruiting
    • Ji Zhu, MD · Contact
    • Ji Zhu, MD · Principal investigator
  • Sun Yat-sen Memorial Hospital/ the Second Affiliated Hospital of Sun Yat-sen University
    Guanzhou, Guangdong, China
    Recruiting
    • Herui Yao, MD · Contact
    • Herui Yao, MD · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
    Not yet recruiting
    • Yan Yu, MD · Contact
    • Yan Yu, MD · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Shujun Yang, MD · Contact
    • Shujun Yang · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Recruiting
    • Yanru Qin, MD · Contact
    • Yanru Qin, MD · Principal investigator
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Not yet recruiting
    • Xiaorong Dong, MD · Contact
    • Xiaorong Dong, MD · Principal investigator
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia, China
    Not yet recruiting
    • Qun Hu, MD · Contact
    • Qun Hu, MD · Principal investigator
  • Xuzhou Center Hospital
    Xuzhou, Jiangsu, China
    Recruiting
    • Yuan Yuan, MD · Contact
    • Yuan Yuan, MD · Principal investigator
  • First Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
    • Wei Li, MD · Contact
    • Wei Li, MD · Principal investigator
  • JILIN Cancer Hospital
    Changchun, Jilin, China
    Not yet recruiting
    • Ying Chen, MD · Contact
    • Ying Chen, MD · Principal investigator
  • Yunnan Cancer Hospital
    Yunnan, Kunming, China
    Not yet recruiting
    • Runxiang Yang, MD · Contact
    • Runxiang Yang, MD · Principal investigator
  • Liaoning Province Cancer Hospital
    Shenyang, Liaoning, China
    Recruiting
    • Yan Zhao, MD · Contact
    • Yan Zhao, MD · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Not yet recruiting
    • Fujian Liu, MD · Contact
    • Fujian Liu, MD · Principal investigator
  • Shanghai Chest Hospital
    Shanghai, Shanghai, China
    Not yet recruiting
    • Shun Lu, MD · Contact
    • Shun Lu, MD · Principal investigator
  • Chongqing University Cancer Hospital
    Chongqing, Sichuan, China
    Recruiting
    • Dewei Li, MD · Contact
    • Dewei Li, MD · Principal investigator
    • Yongsheng Li, MD · Principal investigator
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hanzhou, Zhejiang, China
    Recruiting
    • Yuan Ding, MD · Contact
    • Yuan Ding, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Apr 2025, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2022
First posted
Feb 17, 2022
StartActual
Jun 30, 2022
Primary completionEst.
Apr 30, 2025
CompletionEst.
Apr 30, 2025
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05244551
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Jun 30, 2022
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Aug 12, 2024

Study contacts

Yuan LU
Contact
clinical@abbisko.com
+86 21 68910052

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABSK061

Start the discussion